Scandion Oncology strengthens its Clinical Advisory Board with three new members
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the company has strengthened its Clinical Advisory Board with three international highly experienced Key Opinion Leaders in oncology.With Professor Richard Schilsky already on board since April 2021, the Clinical Advisory Board now consists of four members. The three new members are Professor Josep Tabernero, MD, PhD; Professor Eric Van Cutsem, MD, PhD; and Professor Thomas Seufferlein, MD. “I am thrilled and humbled that we have been able to expand our stellar clinical advisory board with this team of